Grafeel

What is Grafeel?

Grafeel (Filgrastim) is Dr. Reddy’s Biologics’ first biosimilar product that was launched in 2001. Grafeel is used to treat neutropenia (low white blood cells) that is caused by chemotherapy. Filgrastim helps the bone marrow to make new white blood cells.

Storage Conditions

2-8 degrees Celsius (refrigerate), Do not freeze.

Presentation

Vial containing drug + PFS containing drug

Route of Administration:

Subcutaneous (SC) (upon prescription only and administered by a healthcare provider.)

Indications

Neutropenia:

Neutropenia, a decrease in circulating neutrophils (PMNs), weakens the body’s primary defense against bacterial and certain fungal infections. Defined in adults as an absolute neutrophil count (ANC) of 1,500 or fewer per microliter of blood, neutropenia is often caused by chemotherapy or radiation. Other causes include infections, vitamin deficiencies, bone marrow disease, congenital disorders, autoimmune destruction, and hypersplenism.

Neutropenia:

How Filgrastim works?

Mechanism of Action

Grafeel contains filgrastim, a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils. Its mechanism of action involves binding to G-CSF receptors on precursor cells in the bone marrow, activating the JAK-STAT signaling pathway. This leads to the proliferation, differentiation, and maturation of neutrophils, which are then released into the bloodstream. By increasing neutrophil counts, Grafeel helps reduce the risk of infections, especially in patients undergoing chemotherapy.